- Biohaven (BHVN, Financial) unveils positive Phase 1 results for two promising drug candidates at R&D Day.
- BHV-1400 shows up to 81% reduction in disease-causing antibodies for IgA nephropathy.
- BHV-1300 achieves up to 87% reduction in IgG levels, targeting Graves' Disease.
Biohaven Ltd. (BHVN) announced significant progress in its drug development pipeline at their recent R&D Day event. The company's innovative platforms, MoDEâ„¢ and TRAPâ„¢, are leading to advancements in treatments for immunological diseases.
BHV-1400, a pioneering TRAP degrader, demonstrated up to an 81% reduction in galactose-deficient IgA1 (Gd-IgA1) levels, a key pathogenic driver of IgA nephropathy (IgAN). This single subcutaneous dose not only provided sustained effects but also preserved other healthy antibodies, offering a clear advantage over existing therapies. Pivotal trials for BHV-1400 in IgAN are scheduled to commence in 2026.
Similarly, BHV-1300, targeting IgG through Biohaven's MoDE platform, achieved impressive results in Phase 1 trials. The drug showed up to an 87% reduction in IgG levels with a median maximum reduction of 83% within 18 days. These results pave the way for pivotal trials in Graves' Disease, planned for the latter half of 2025.
Both of these drug candidates presented favorable safety profiles, with predominantly mild, self-resolving adverse events and no serious safety concerns. This positions them as potential first-in-class treatments designed to address the root causes of these diseases with precision and reduced impact on overall immune function.
